Find clinical trials for Melanoma in Milano, Lombardia

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer

Carcinoma

Squamous Cell Carcinoma of Head and Neck

Non-Small-Cell Lung Carcinoma

Renal Cell Carcinoma

Lung Cancer

Squamous Cell Carcinoma

Melanoma trials near Milano, Lombardia, ITA:

Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma (NEO-TIM)

given in combination or sequence may have an anti-tumour activity and may reduce the risk of relapse in patients with high-risk resectable melanoma...

Active, not recruiting

Melanoma

Drug: Cobimetinib 20 MG Oral Tablet

Drug: Atezolizumab 1200 MG in 20 ML Injection

Phase 2

Fondazione Melanoma Onlus

Milano, Italy and 5 other locations

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma...

Enrolling

Uveal Melanoma

Drug: Darovasertib

Phase 2

Ideaya Biosciences

Milan, Italy and 24 other locations

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

(PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma...

Enrolling

Melanoma

Drug: EU-authorized Nivolumab

Drug: ABP 206

Phase 3

Amgen

Milano, Italy and 5 other locations

Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma

This is open label, single arm study for pts with stage IIIB-IV melanoma, accordingly with AJCC staging criteria (8th ed.), with potentially...

Active, not recruiting

Melanoma

Drug: Ipilimumab

Phase 2

European Institute of Oncology

Milano, Italy

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma...

Enrolling

Advanced Melanoma

Drug: Tebentafusp

Drug: Tebentafusp with Pembrolizumab

Phase 2, Phase 3

Immunocore

Milano, Italy and 70 other locations

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...

Enrolling

Melanoma

Unresectable Melanoma

Biological: Pembrolizumab with Optional Crossover Period

Biological: Lifileucel plus Pembrolizumab

Phase 3

Iovance Biotherapeutics

Milan, Italy and 45 other locations

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

binimetinib, and pembrolizumab) given together for the treatment of melanoma that:* is advanced or metastatic (spread to other parts of the ...

Active, not recruiting

Melanoma

Drug: Binimetinib

Drug: Encorafenib

Phase 3

Pfizer

Milano, Italy and 227 other locations

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)

the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma...

Active, not recruiting

Melanoma

Drug: Placebo to match Encorafenib ; Placebo to match Binimetinib

Drug: Encorafenib and Binimetinib

Phase 3

Pierre Fabre

Milano, Italy and 154 other locations

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma (PORTSIDE)

medicines (ipilimumab and nivolumab) given for the treatment of melanoma.Melanoma is a type of cancer that starts in the cells that...

Active, not recruiting

Melanoma

Drug: encorafenib

Drug: ipilimumab

Phase 2

Pfizer

Milano, Italy and 62 other locations

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma...

Enrolling

Melanoma

Drug: ABP 206

Drug: Nivolumab

Phase 3

Amgen

Milano, Italy and 3 other locations

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms

Find clinical trials for Melanoma in .css-epvm6{white-space:nowrap;}Milano, Lombardia

Related conditions:

Melanoma trials near Milano, Lombardia, ITA:

Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma (NEO-TIM)

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma (PORTSIDE)

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

Find clinical trials for Melanoma in Milano, Lombardia